Net Income

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

A single-dose therapy wiped out aggressive glioblastoma tumors in a landmark pre-clinical study, paving the way for human trials in 2026.

As AI and automation reshape global tax, a new online certificate from IBFD and VU Amsterdam aims to equip professionals with crucial, future-proof skills.

A new report reveals a massive security blind spot. Unmanaged apps, fueled by AI adoption, are causing data breaches, audit failures, and huge financial losses.

With most OUD patients lacking access to care, a new grant funds research into payment models that reward results, not just services.

The energy tech giant completes its EMEA business divestiture to AURELIUS, sharpening focus on the Americas and APAC while reshaping Europe's grid market.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.

After a multi-year legal battle over a construction project ended in a total loss, Colleyville taxpayers are footing a $1.37 million bill.

The nation's top farm co-op faces mounting losses from biofuel rules and weak grain markets, signaling wider distress across the American heartland.

Galloway Capital Partners takes a 5.44% stake in Chegg, arguing the ed-tech firm is undervalued and a strategic split could revive its fortunes.

Absci will showcase its generative AI drug discovery platform at a key healthcare conference, highlighting its ambitious pipeline for hair loss and endometriosis.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

As uranium prices soar, one explorer uses advanced 3D modeling and AI to unlock new discovery potential in Canada's richest uranium district.

As Spectral AI preps its revolutionary DeepView wound scanner for launch, new CFO David McGuire brings crucial public company expertise to a pivotal transition.

Ovid Therapeutics is spotlighting a novel drug class targeting KCC2, a key brain protein. Could this be the key to treating psychosis and epilepsy?

CorTec's brain-computer interface gets FDA Breakthrough status, offering new hope for restoring movement in millions of chronic stroke survivors.

After a Nasdaq delisting for compliance failures, Captivision is abandoning its tech past for a risky new venture: a gold rush in Montana.

DPM Metals reports strong Q1 results, balancing the Vareš mine ramp-up, Ada Tepe's closure, and aggressive Serbian exploration, all while rewarding investors.

Amid global volatility, B2PRIME Group announced record 2025 profits, a 5x surge in volume, and eliminated all debt, setting a new bar for resilience.

Stellar Cyber's 'Most Innovative' award at RSAC 2026 highlights a major shift toward AI that empowers, not replaces, human security experts.